FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to a pharmaceutical composition for treating or preventing social dysfunction in a subject; treating or preventing a psychotic disorder in a subject; treating a subject suffering or recovering from a psychoactive substance abuse disorder and/or striving to maintain continued abstinence from said substance. Disclosed composition contains a pharmaceutically acceptable carrier and a compound having the formula given below, or a pharmaceutically acceptable salt thereof.
EFFECT: present application discloses methods of treating said neurological and psychiatric disorders using said pharmaceutical composition or the above compound, as well as use of said compound.
20 cl, 20 dwg, 30 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING MAJOR DEPRESSION IN HUMAN | 2007 |
|
RU2445973C2 |
| COMPOUNDS MODULATING INTRACELLULAR CALCIUM | 2008 |
|
RU2465272C2 |
| METHODS FOR TREATMENT OF POST-TRAUMATIC STRESS DISORDER | 2011 |
|
RU2775783C2 |
| METHODS OF TREATMENT OF BIPOLAR DISORDER | 2011 |
|
RU2653408C2 |
| USE OF N,N"-SUBSTITUTED 3,7-DIAZABICYCLO[3_3_1]NONANES DERIVATIVES FOR DEPRESSION THERAPY | 2019 |
|
RU2726313C1 |
| COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL DISEASES | 2013 |
|
RU2684097C2 |
| NEUROACTIVE COMPOUNDS AND THEIR APPLICATION METHODS | 2015 |
|
RU2764702C2 |
| NMDA ANTAGONIST PRODRUGS | 2014 |
|
RU2695372C2 |
| (+)-ALPHA-DIHYDROTETRABENAZINE FOR USE IN TREATMENT OF MOTOR DISORDER | 2018 |
|
RU2771164C2 |
| DPP-IV INHIBITORS FOR TREATMENT OF NEURODEGENERATION AND COGNITIVE DISORDERS | 2005 |
|
RU2394570C2 |
